Windtree Moves Into Fintech With Planned Acquisition of Commercial Lending Platform

Windtree Therapeutics

WARRINGTON, PAWindtree Therapeutics, Inc. (OTC: WINT) said it has signed a letter of intent to acquire CommLoan, Inc., a commercial real estate lending technology company, in a move that continues Windtree’s strategy of diversifying beyond therapeutics into revenue-generating businesses.

CommLoan operates what it describes as the first true commercial mortgage marketplace. Its CUPID platform connects borrowers and loan originators with hundreds of active lenders nationwide, allowing users to compare terms across multifamily, retail, office, industrial, healthcare and SBA-backed property types. The Scottsdale-based company, founded in 2014, markets its platform as a more transparent and efficient approach to sourcing middle-market commercial loans.

READ:  Savara Grants Equity Awards to 24 New Employees

Under the deal, CommLoan will become a Windtree subsidiary and retain key employees. Windtree has provided bridge financing to support the transition, signaling its intention to scale the fintech business quickly once the acquisition closes.

“Windtree is pleased to add a revenue generating fintech business as our subsidiary,” said CEO Jed Latkin. He said CommLoan’s proprietary data assets and use of software and AI to simplify loan origination give Windtree a growth engine that would have been difficult to replicate internally.

CommLoan founder and CEO Mitch Ginsberg said aligning with Windtree strengthens the company’s ability to expand while maintaining control of its long-term strategy. “We’ve spent years developing technology that revolutionizes how commercial real estate loans are originated,” he said. “Joining forces with Windtree positions us to accelerate that mission.”

READ:  ICYMI: 1031 CORP. Acquires Assets of 1031 Exchange Specialists in New Jersey

The acquisition marks a notable step for Windtree, which has been seeking to broaden its portfolio with businesses capable of generating more immediate revenue and profit. The company said the deal fits its long-term objective of building diversified operating divisions beyond its core therapeutics programs.

Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.